The deficit syndrome in schizophrenia: Implications for the treatment of negative symptoms

European Psychiatry

Volumn 19, Issue 1, 2004, Pages 21-26

  Arango, Celso ^a   Buchanan, Robert W ^a   Kirkpatrick, Brian ^a   Carpenter, William T ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; CYCLOSERINE; GLYCINE; HALOPERIDOL; KETAMINE; NEUROLEPTIC AGENT; PHENCYCLIDINE;

ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MENTAL PATIENT; NEGATIVE SYNDROME; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RATING SCALE; RISK FACTOR; SYMPTOMATOLOGY;

EID: 1142285269     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2003.10.004     Document Type: Article

References (35)

1. Dementia praecox or the Group of Schizophrenias. 1950;International Universities Press, New York, NY.
2. Carpenter W.T. Jr, Arango C., Kirkpatrick B., Buchanan R.W. Deficit psychopathology and a paradigm shift in schizophrenia research. Biol Psychiatry. 46:1999;352-360.
3. Carpenter W.T. Jr, Buchanan R.W., Kirkpatrick B., Tamminga C., Wood F. Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry. 50:1993;825-831.
4. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 58:2001;165-171.
5. Kraepelin E. Dementia praecox and paraphrenia. 1971;Krieger, New York. [Original work published 1919].
6. Rado S. Psychoanalysis of behavior: collected papers. 1956;Grune & Stratton, New York.
7. Meehl P.E. Schizotaxia, schizotypy, and schizophrenia. Am Psychol. 17:1962;827-838.
8. Jaspers K. General psychopathology. 7th ed:1963;Manchester University Press, Manchester. [Hoenig J, Hamilton MW, Trans.].
9. Carpenter W.T. Jr, Bartko J.J., Carpenter C.L., Strauss J.S. Another view of schizophrenia subtypes. A report from the international pilot study of schizophrenia. Arch Gen Psychiatry. 33:1976;508-516.
10. Carpenter W.T. Jr, Strauss J.S. The prediction of outcome in schizophrenia. IV: eleven-year follow-up of the Washington IPSS cohort. J Nerv Ment Dis. 179:1991;517-525.
11. Buchanan R.W., Carpenter W.T. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis. 182:1994;193-204.
12. Andreasen N.C., Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry. 39:1982;789-794.
13. Crow T.J. Molecular pathology of schizophrenia: more than one disease process? Br Med J. 280:1980;66-68.
14. Carpenter W.T. Jr, Heinrichs D.W., Wagman A.M.I. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 145:1988;578-583.
15. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. Jr. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 30:(2):1989;119-123.
16. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Rep. 10:1962;799-812.
17. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry. 7:(Suppl):1989;49-58.
18. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 13:1987;261-276.
19. Blyler C.R., Gold J.M. Cognitive effects of typical antipsychotic treatment: another look. Sharma T., Harvey P.D. Cognition in schizophrenia: impairments, importance, and treatment strategies. 2000;241-265 Oxford University Press, New York.
20. Tek C., Kirkpatrick B., Buchanan R.W. A five-year followup study of deficit and nondeficit schizophrenia. Schizophr Res. (49):2001;253-260.
21. Tamminga C.A., Thaker G.K., Buchanan R., Kirkpatrick B., Alphs L.D., Chase T.N., et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry. 49:(7):1992;522-530.
22. Buchanan R.W., Breier A., Kirkpatrick B., Elkashef A., Munson R.C., Gellad F., et al. Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry. 150:(1):1993;59-65.
23. Quarantelli M., Larobina M., Volpe U., Amati G., Tedeschi E., Ciarmiello A., et al. Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and nondeficit schizophrenia. Neuroimage. 17:(1):2002;373-384.
24. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 45:1988;789-796.
25. Conley R., Richardson C., Kent D., Gounaris C., Zaremba S. Clozapine response varies in deficit vs. non-deficit schizophrenic subjects. Biol Psychiatry. 35:1994;746.
26. Buchanan R.W., Breier A., Kirkpatrick B., Ball P., Carpenter W.T. Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 155:1998;751-760.
27. Kane J.M., Marder S.R., Schooler N.R., Wirshing W.C., Umbricht D., Baker R.W., et al. Clozapine and haloperidol in moderately refractory schizophrenia: a six-month randomized and double-blind comparison. Arch Gen Psychiatry. 58:2001;965-972.
28. Rosenheck R., Dunn L., Peszke M., Cramer J., Xu W., Thomas J., et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry. 156:1999;88-93. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
29. Tamminga C. Glutamatergic aspects of schizophrenia. Br J Psychiatry. 37:(Suppl):1999;12-15.
30. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 56:(1):1999;21-27.
31. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 56:(1):1999;29-36.
32. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 44:1998;1081-1089.
33. Tsai G.E., Yang P., Chung L.C., Tsai I.C., Tsai C.W., Coyle J.T. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 156:(11):1999;1822-1825.
34. Boyer P., Lecrubier Y., Puech A.J., Dewailly J., Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry. 166:1995;68-72.
35. Paillere-Martinot M.L., Lecrubier Y., Martinot J.L., Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry. 152:1995;130-134.